Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Consensus PT from Analysts
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has received an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last […]
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has received an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last […]
